We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Biogen Inc (BIIB) USD (CDI)

Sell:$203.96 Buy:$204.05 Change: $1.29 (0.63%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
Sell:$203.96
Buy:$204.05
Change: $1.29 (0.63%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
Sell:$203.96
Buy:$204.05
Change: $1.29 (0.63%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.

Contact details

Address:
225 Binney St
CAMBRIDGE
02142-1031
United States
Telephone:
+1 (781) 4642000
Website:
https://www.biogen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BIIB
ISIN:
US09062X1037
Market cap:
$29.66 billion
Shares in issue:
146.45 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michel Vounatsos
    Chief Executive Officer, Director
  • Michael McDonnell
    Chief Financial Officer, Executive Vice President
  • Ginger Gregory
    Chief Human Resource Officer, Executive Vice President
  • Susan Alexander
    Executive Vice President, Chief Legal Officer and Secretary
  • Alphonse Galdes
    Executive Vice President, Pharmaceutical Operations and Technology
  • Chirfi Guindo
    Executive Vice President, Global Product Strategy and Commercialization
  • Rachid Izzar
    Executive Vice President, Head of Alzheimers Disease and Dementia Business Unit
  • Robin Kramer
    Senior Vice President, Chief Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.